FDA Invites Comment On Continuous Manufacturing

Draft guidance on quality considerations for continuous manufacturing has been published by the US Food and Drug Administration with a 90-day comment period.

ContinuousProduction
The FDA Has Issued Draft Guidance On Continuous Manufacturing • Source: Shutterstock

Draft guidance on quality considerations for continuous manufacturing has been published by the US Food and Drug Administration (FDA). With a 90-day period for interested parties to submit comments and suggestions, the document covers small-molecule oral solid-dosage forms regulated by the center for drug evaluation and research (CDER).

Describing “key quality considerations”, the guidance gives recommendations for how abbreviated new drug application (ANDA) and new drug application (NDA)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Business

Beyond ‘Vanilla’ Generics: How Lupin Is Evolving To Stay Ahead Of The UK Competition

 
• By 

As UK players face increasing competitive pressures on “vanilla” generics – including potential new market entrants from China – Ben Ellis, Lupin’s UK and Ireland general manager, explains how the company is focusing on more complex opportunities that require a hybrid generic and branded mindset.

Teva Continues Push Beyond Generics in Fosun Immunotherapy Tie-Up

 
• By 

Teva has agreed to partner with China’s Fosun Pharma to develop TEV-56278, a targeted cancer immunotherapy, marking the next step in its continued pivot from its generics roots toward complex biologics and innovative oncology treatments. The deal covers key Asian markets, including mainland China, w

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.